Showing 1971-1980 of 2123 results for "".
- DHODH Inhibitor Reduces Lesions Significantly in Relapsing-Remitting MShttps://practicalneurology.com/news/dhodh-inhibitor-reduces-lesions-significantly-in-relapsing-remitting-ms/2469343/A phase 2 clinical trial (NCT03846219) of a selective oral Dihydroorotate dehydrogenase (DHODH) inhibitor (IMU-838; Immunic, New York, NY) provided a significant reduction in lesions in participan
- FDA Approves ppCBD to Treat Seizures Associated with Tuberous Sclerosis Complexhttps://practicalneurology.com/news/fda-approves-ppcbd-to-treat-seizures-associated-with-tuberous-sclerosis-complex/2469341/The Food and Drug Administration (FDA) has approved prescription pharmaceutical cannabidiol (ppCBD) (Epidiolex; GW Pharmaceuticals, Carlsbad, CA) oral solution to treat seizures associated with tuberous sclerosis complex (TSC) in patients age 1 year or more. Along with this new indication, the ag
- FDA Approves New Oxybates Compound for Cataplexy or Excessive Daytime Sleepiness of Narcolepsyhttps://practicalneurology.com/news/fda-approves-new-oxybate-compound-for-cataplexy-or-excessive-daytime-sleepiness-of-narcolepsy/2469330/The Food and Drug Administration (FDA) approved a calcium, magnesium, potassium, and sodium oxybates oral solution (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in individuals age 7 years and more with n
- FDA Approves Fenfluramine for Treatment of Seizures Associated with Dravet Syndromehttps://practicalneurology.com/news/fda-approves-fenfluramine-for-treatment-of-seizures-associated-with-dravet-syndrome/2469308/The Food and Drug Administration (FDA) has approved fenfluramine (Fintepla; Zogenix, Emeryville, CA), oral solution for treatment of seizures associated with Dravet syndrome (DS) in individuals age 2 years or more. Fenfluramine will be launched through a restricted distribution program, called th
- Phase 2 Clinical Trial for Stem-Cell Treatment of Alzheimer Disease Plannedhttps://practicalneurology.com/news/phase-2-clinical-trial-for-stem-cell-treatment-of-alzheimer-disease-planned/2469305/A phase 2 clinical trial to evaluate the safety and efficacy of treatment in individuals with prodromal to mild Alzheimer disease (AD) is planned for the autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY). The program is be
- Children Treated With Nusinersen Continue Meeting Developmental Motor Milestoneshttps://practicalneurology.com/news/children-treated-with-nusinersen-continue-meeting-developmental-motor-milestones/2469290/When used as prolonged treatment for children with spinal muscular atrophy (SMA), nusinersen (Spinraza; Biogen Inc., Cambridge, MA) results in progressive improvements in motor function. The early and continuous treatment with nusinersen for 4.8 years enabled unprecedented survival in participant
- Investigation of Foralumab for Alzheimer Disease Treatment Will Continue to Phase 2https://practicalneurology.com/news/investigation-of-foralumab-for-alzheimer-disease-treatment-will-continue-to-phase-2/2469286/Nasally administered foralumab (Tiziana Life Sciences, New York, NY) has showed delays in disease processes underlying the progression of Alzheimer disease (AD) in animal models . Based on those results, the investigation of foralumab for AD will continue to phase 2 clinical trials. Foralum
- Phase 2 Clinical Trial Initiated for Bryostatin Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/phase-2-clinical-trial-initiated-for-bryostatin-treatment-of-alzheimer-disease/2469281/Researchers will evaluate the long-term therapeutic effect of bryostatin-1 (Neurotrope, New York, NY) for Alzheimer disease (AD) in a new phase 2 clinical study (NCT02221947). An estimated 10
- Blood Test May Help Predict Disease Progression in Individuals with Multiple Sclerosishttps://practicalneurology.com/news/blood-test-may-help-predict-disease-progression-in-individuals-with-multiple-sclerosis/2469268/A study published in Neurology shows that a blood test may help predict worsening of multiple sclerosis (MS) likely to occur within the next year. The test can detect a neurofilament light (NfL) cha
- New Social Networking Platform for the Multiple Sclerosis Communityhttps://practicalneurology.com/news/new-social-networking-platform-for-the-multiple-sclerosis-community/2469254/A new free anonymous AI-powered social networking and navigation platform, BelongMS (Belong.Life, New York, NY), has been launched for individuals with multiple sclerosis (MS), caregivers, and healthcare professionals. The app can be downloaded for Android and iOS. The new app follows t